| 2022年年报 | 2022年中报 | |
|---|---|---|
| 营业收入(元) | ||
| CMC/CMO(元) | 43,588,722.55 | 11,720,641.06 |
| 吡拉西坦注射剂(元) | 146,440,174.53 | 70,774,931.20 |
| 复方消化酶胶囊(元) | 207,037,184.61 | 97,311,962.65 |
| 甲钴胺片(元) | 52,280,623.10 | 25,149,494.95 |
| 注射用胰激肽原酶(元) | 39,379,380.50 | 17,934,690.24 |
| 奥曲肽注射剂(元) | 25,930,044.91 | - |
| 其他主营业务(元) | - | 44,987,246.71 |
| 其他(元) | 92,718,295.19 | 44,987,246.71 |
| 营业成本(元) | ||
| CMC/CMO(元) | 24,370,881.63 | 7,141,108.41 |
| 吡拉西坦注射剂(元) | 18,597,928.27 | 10,356,698.33 |
| 复方消化酶胶囊(元) | 53,424,858.62 | 25,411,365.73 |
| 甲钴胺片(元) | 19,334,797.78 | 10,007,160.41 |
| 注射用胰激肽原酶(元) | 3,861,718.08 | 1,887,097.31 |
| 奥曲肽注射剂(元) | 2,475,657.27 | - |
| 其他主营业务(元) | - | 11,884,150.43 |
| 其他(元) | 29,139,747.85 | 11,884,150.43 |
| 毛利(元) | ||
| CMC/CMO(元) | 19,217,840.92 | 4,579,532.65 |
| 吡拉西坦注射剂(元) | 127,842,246.26 | 60,418,232.87 |
| 复方消化酶胶囊(元) | 153,612,325.99 | 71,900,596.92 |
| 甲钴胺片(元) | 32,945,825.32 | 15,142,334.54 |
| 注射用胰激肽原酶(元) | 35,517,662.42 | 16,047,592.93 |
| 奥曲肽注射剂(元) | 23,454,387.64 | - |
| 其他主营业务(元) | - | 33,103,096.28 |
| 其他(元) | 63,578,547.34 | 33,103,096.28 |
| 毛利率(%) | ||
| CMC/CMO(%) | 44.09 | 39.07 |
| 吡拉西坦注射剂(%) | 87.30 | 85.37 |
| 复方消化酶胶囊(%) | 74.20 | 73.89 |
| 甲钴胺片(%) | 63.02 | 60.21 |
| 注射用胰激肽原酶(%) | 90.19 | 89.48 |
| 奥曲肽注射剂(%) | 90.45 | - |
| 其他主营业务(%) | - | 73.58 |
| 其他(%) | 68.57 | 73.58 |
| 收入构成(%) | ||
| CMC/CMO(%) | 7.18 | 3.75 |
| 吡拉西坦注射剂(%) | 24.11 | 22.62 |
| 复方消化酶胶囊(%) | 34.09 | 31.10 |
| 甲钴胺片(%) | 8.61 | 8.04 |
| 注射用胰激肽原酶(%) | 6.48 | 5.73 |
| 奥曲肽注射剂(%) | 4.27 | - |
| 其他主营业务(%) | - | 14.38 |
| 其他(%) | 15.27 | 14.38 |
| 毛利构成(%) | ||
| CMC/CMO(%) | 4.21 | 1.95 |
| 吡拉西坦注射剂(%) | 28.03 | 25.79 |
| 复方消化酶胶囊(%) | 33.67 | 30.69 |
| 甲钴胺片(%) | 7.22 | 6.46 |
| 注射用胰激肽原酶(%) | 7.79 | 6.85 |
| 奥曲肽注射剂(%) | 5.14 | - |
| 其他主营业务(%) | - | 14.13 |
| 其他(%) | 13.94 | 14.13 |